Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

BIIB

Biogen Inc

Jul 26 • 04:00PM ET

211.17

Dollar change -16.27
Percentage change -7.15	%

Healthcare • Drug Manufacturers - General • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO VO QQQ SPY IVV VTV XLV IBB VOE

Index	NDX, S&P 500	P/E	26.38	EPS (ttm)	8.01	Insider Own	0.77%	Shs Outstand	144.90M	Perf Week	-6.73%
Market Cap	30.75B	Forward P/E	12.21	EPS next Y	17.30	Insider Trans	-0.09%	Shs Float	144.48M	Perf Month	-5.92%
Income	1.17B	PEG	6.68	EPS next Q	4.01	Inst Own	89.51%	Short Float	2.51%	Perf Quarter	4.30%
Sales	9.29B	P/S	3.31	EPS this Y	5.96%	Inst Trans	0.82%	Short Ratio	3.52	Perf Half Y	-14.23%
Book/sh	104.48	P/B	2.02	EPS next Y	10.90%	ROA	4.56%	Short Interest	3.63M	Perf Year	-20.39%
Cash/sh	7.38	P/C	28.62	EPS next 5Y	3.95%	ROE	8.04%	52W Range	189.44 - 278.95	Perf YTD	-18.39%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-18.05%	ROI	5.32%	52W High	-24.30%	Beta	-0.04
Dividend TTM	-	Quick Ratio	1.32	Sales past 5Y	-4.53%	Gross Margin	68.31%	52W Low	11.47%	ATR (14)	7.26
Dividend Ex-Date	-	Current Ratio	2.10	EPS Y/Y TTM	-62.75%	Oper. Margin	18.67%	RSI (14)	35.17	Volatility	2.92% 2.96%
Employees	7570	Debt/Eq	0.46	Sales Y/Y TTM	-2.49%	Profit Margin	12.56%	Recom	1.67	Target Price	280.90
Option/Short	Yes / Yes	LT Debt/Eq	0.44	EPS Q/Q	0.93%	Payout	0.00%	Rel Volume	2.14	Prev Close	227.44
Sales Surprise	-0.80%	EPS Surprise	5.78%	Sales Q/Q	-5.62%	Earnings	Aug 01 BMO	Avg Volume	1.03M	Price	211.17
SMA20	-7.36%	SMA50	-7.06%	SMA200	-8.71%	Trades		Volume	2,209,242	Change	-7.15%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-14-24	Reiterated	Needham	Buy	$305 → $300
Feb-14-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$315 → $240
Jan-24-24	Downgrade	UBS	Buy → Neutral	$311 → $276
Dec-20-23	Resumed	Cantor Fitzgerald	Overweight	$311
Dec-07-23	Upgrade	Raymond James	Mkt Perform → Outperform	$283
Sep-06-23	Initiated	HSBC Securities	Buy	$360
Jul-27-23	Initiated	Scotiabank	Sector Outperform	$327
Jul-24-23	Reiterated	UBS	Buy	$346 → $335
May-01-23	Upgrade	Guggenheim	Neutral → Buy	$270 → $350
Apr-17-23	Upgrade	Piper Sandler	Neutral → Overweight	$280 → $346
Oct-26-22	Upgrade	Goldman	Neutral → Buy	$220 → $370
Oct-13-22	Upgrade	Stifel	Hold → Buy	$223 → $299
Oct-07-22	Upgrade	Argus	Hold → Buy	$300
Sep-28-22	Upgrade	Robert W. Baird	Neutral → Outperform	$224 → $340
Sep-28-22	Upgrade	Mizuho	Neutral → Buy	$207 → $270
Sep-28-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$217 → $360
Apr-18-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$235 → $265
Mar-08-22	Downgrade	Stifel	Buy → Hold	$304 → $223
Mar-03-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$227 → $248
Feb-04-22	Reiterated	Wolfe Research	Peer Perform	$244 → $217

Show Previous Ratings

Today 05:12PM	S&P 500 Gains and Losses Today: 3M Stock Skyrockets After Beat-and-Raise Report (Investopedia) -7.15%
04:15PM	Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug (Investor's Business Daily)
01:14PM	Top Stock Movers Now: 3M, Charter Communications, Dexcom, and More (Investopedia)
10:48AM	EU Rejection of Alzheimers Drug Is Another Disappointment for Biogen (Barrons.com)
10:21AM	Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events (Benzinga)
09:48AM	Loading…
09:48AM	European committee says Alzheimer's treatment Leqembi shouldn't get marketing approval (Associated Press Finance)
08:00AM	Is Eli Lilly Stock A Sell On A Second Stumble In Obesity Treatment? (Investor's Business Daily)
07:20AM	Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union (GlobeNewswire)
Jul-25-24 10:02AM	Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for (Zacks)
04:52AM	Sage and Biogens SAGE-324 shows no benefit in essential tremor trial (Clinical Trials Arena)
Jul-24-24 04:07PM	Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails (Investor's Business Daily)
10:34AM	Sage Therapeutics Stock Slides as Pipeline Thins (Barrons.com)
09:37AM	Is Biogen (BIIB) an Underappreciated Stock? (Insider Monkey)
08:10AM	Biogen, Sage tremor drug fails key trial (BioPharma Dive)
06:30AM	Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor (Business Wire)
03:52AM	Loading…
Jul-23-24 03:52AM	Nanotechnology in medicine: Who are the leading public companies? (Medical Device Network)
Jul-22-24 04:27PM	Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong (Investor's Business Daily)
08:14AM	Ionis plots next steps for Angelman drug Biogen passed on (BioPharma Dive)
01:12AM	Sage Therapeutics/Biogens episodic therapy zuranolone could change MDD treatment (Clinical Trials Arena)
Jul-17-24 09:50AM	Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term (Zacks)
Jul-16-24 04:02PM	Three Surprising Names That Could Be On Biogen's Buyout Shortlist (Investor's Business Daily)
12:45PM	Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights BIIB (GlobeNewswire)
11:55AM	Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense (Investor's Business Daily)
05:10AM	Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing (GlobeNewswire)
04:00AM	Biogen Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BIIB (PR Newswire)
Jul-12-24 08:00AM	Eli Lilly Overcomes Biden-Tied Stumble To Rise Again Is Lilly Stock Now A Buy? (Investor's Business Daily)
Jul-10-24 03:25PM	ADM Hires 3M CFO Amid Government Investigation (Investopedia)
01:08PM	Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights BIIB (GlobeNewswire)
Jul-09-24 07:51PM	Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB (PR Newswire)
Jul-05-24 06:20AM	3 Highly Rated Biotech Stocks for Your July Buy List (InvestorPlace)
12:37PM	Loading…
Jul-03-24 12:37PM	Top Stock Movers Now: Tesla, Paramount Global, Biogen, and More (Investopedia)
11:14AM	Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence (Pharmaceutical Technology)
11:14AM	FDA Approves Eli Lilly's Alzheimer's Drug Kisunla (Investopedia)
08:00AM	Biden Just Knocked Eli Lilly Stock Off Its Pedestal Is It A Buy Or A Sell? (Investor's Business Daily)
07:55AM	5 Things to Know Before the Stock Market Opens (Investopedia)
Jul-02-24 04:13PM	Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug (Investor's Business Daily)
02:16PM	Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai (Investor's Business Daily)
12:45PM	Biogen (BIIB) Slipped on Lower-Than-Expected Revenue Growth (Insider Monkey)
09:16AM	Biogen Completes Acquisition of Human Immunology Biosciences (GlobeNewswire)
Jul-01-24 01:00AM	10 clinical trials to watch in the second half of 2024 (BioPharma Dive)
Jun-29-24 08:45PM	C4 Therapeutics, Inc. (CCCC): Is This the Best Biotech Penny Stock to Buy Now? (Insider Monkey)
Jun-28-24 06:13AM	Eisai and Biogen launch LEQEMBI for Alzheimers in China (Pharmaceutical Technology)
Jun-27-24 09:02PM	Eisai and Biogen launch Alzheimer's drug Leqembi in China (Reuters)
07:39PM	LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China (GlobeNewswire)
02:33PM	Eli Lilly Has Sprinted 55% Higher This Year Is It A Buy On The Weight-Loss Opportunity? (Investor's Business Daily)
Jun-26-24 05:45AM	Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB (PR Newswire)
03:12AM	Pharma M&A: The top high value deals in 2023 (Pharmaceutical Technology)
Jun-25-24 08:37AM	Is the Options Market Predicting a Spike in Biogen (BIIB) Stock? (Zacks)
Jun-24-24 09:50AM	Biogen Inc. (BIIB) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
07:30AM	TOFIDENCE (tocilizumab), a Biosimilar Referencing ROACTEMRA , Approved in the European Union (GlobeNewswire)
Jun-20-24 01:38PM	Is Eli Lilly Stock A Buy After FDA Advisors Back Its Alzheimer's Drug? (Investor's Business Daily)
Jun-17-24 07:00AM	Two Is Better Than One in the Alzheimers Market (The Wall Street Journal)
01:12AM	ALS pipeline suffers a major hit as Biogens Tofersen fails phase iii trial (Clinical Trials Arena)
Jun-15-24 04:00PM	The 3 Best Healthcare Stocks to Buy in June 2024 (InvestorPlace)
Jun-14-24 06:45PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
05:45AM	Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB (PR Newswire)
Jun-11-24 04:07PM	Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower (Investor's Business Daily)
12:25PM	FDA Advisers Like Lillys Alzheimers Drug. Its Good News for Biogen. (Barrons.com)
12:20PM	Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win (Investor's Business Daily)
08:45AM	Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises (GlobeNewswire)
08:22AM	Donanemab approval would fuel growth of amyloid-blocking Alzheimers drugs, analysts say (BioPharma Dive)
07:35AM	5 Things to Know Before the Stock Market Opens (Investopedia)
Jun-10-24 10:12PM	Eli Lilly Stock Gains After FDA Advisors Recommend Alzheimer's Drug Donanemab (Investopedia)
05:17PM	FDA Panelists Unanimously Back Eli Lilly's Biogen-Rivaling Alzheimer's Drug (Investor's Business Daily)
04:18PM	FDA panel votes unanimously for Eli Lilly's Alzheimer's treatment (Yahoo Finance)
10:27AM	Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug (Investor's Business Daily)
09:54AM	Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance (Zacks)
Jun-09-24 07:37PM	FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease (GlobeNewswire)
Jun-07-24 02:00PM	Eli Lilly Is Trading At A Record High Ahead Of A Key FDA Meeting Is It A Buy? (Investor's Business Daily)
11:41AM	Analyst Report: Biogen Inc. (Morningstar Research)
Jun-06-24 05:23PM	The 3 Most Undervalued Pharma Stocks to Buy in June 2024 (InvestorPlace)
09:50AM	Here's Why Biogen Inc. (BIIB) is a Strong Momentum Stock (Zacks)
05:45AM	Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB (PR Newswire)
Jun-03-24 07:30AM	Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel (GlobeNewswire)
Jun-02-24 07:00AM	Top Stocks To Watch in June (Investopedia)
May-31-24 12:25PM	Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder (Benzinga)
11:42AM	Biogen Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky for More Information BIIB (GlobeNewswire)
10:17AM	Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody (Zacks)
08:00AM	How To Invest: Using Shorter-Term Moving Averages To Trade Stocks (Investor's Business Daily)
04:25AM	European Commission approves Biogens QALSODY for ALS treatment (Pharmaceutical Technology)
May-30-24 04:51PM	Biogen Receives European Commission Approval for QALSODY (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS (GlobeNewswire)
08:30AM	Is Eli Lilly Stock A Buy On A Recent Crohn's Disease-Related Rally? (Investor's Business Daily)
May-29-24 10:27AM	Interim results of IGNAZ trial sheds positive light on felzartamab for IgAN (Clinical Trials Arena)
07:02AM	Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion (GlobeNewswire)
May-28-24 11:21AM	Amyotrophic Lateral Sclerosis Market On Track For USD 1,271.6 Mn Revenue By 2033, Growing At 6.5% CAGR Dimension Market Research (GlobeNewswire)
May-27-24 06:35AM	South Koreas MFDS approves Eisai-Biogens LEQEMBI for Alzheimers (Pharmaceutical Technology)
03:02AM	The Biggest Biotechnology Company in Europe (Insider Monkey)
May-25-24 11:15PM	The Biggest Publicly Traded Biotech Company (Insider Monkey)
11:10PM	20 Biggest Publicly Traded Biotech Companies (Insider Monkey)
May-24-24 11:31AM	Why Is Biogen (BIIB) Up 7.7% Since Last Earnings Report? (Zacks)
May-23-24 10:06AM	Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline (Zacks)
08:54AM	Biogen enters deal to acquire HI-Bio for $1.8bn (Pharmaceutical Technology)
May-22-24 07:28PM	Biogen Buys Biotech Firm HI-Bio to Boost Its Immunology Portfolio (Investopedia)
09:55AM	Biogen is buying up an immune drug developer for $1.8 billion (Quartz)
08:25AM	Biogen says hello to HI-Bio, inking $1.15B buyout to expand in immunology (FierceBiotech.com)
07:37AM	Biogen in up to $1.8 billion deal as rare diseases take center stage (Reuters)
07:30AM	Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences (GlobeNewswire)
07:19AM	Biogen, looking to diversify, acquires immune drugmaker HI-Bio for $1.15B (BioPharma Dive)
May-21-24 09:50AM	Why Biogen Inc. (BIIB) is a Top Momentum Stock for the Long-Term (Zacks)
May-17-24 06:15AM	Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 (InvestorPlace)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Keeney Adam	Head of Corporate Development	May 01 '24	Option Exercise	0.00	938	0	938	May 03 08:00 PM
Singhal Priya	Head of Development	Apr 02 '24	Sale	213.09	93	19,817	4,886	Apr 03 08:24 PM
Murphy Nicole	Head of Pharm Ops and Tech	Apr 01 '24	Option Exercise	0.00	240	0	9,751	Apr 03 08:11 PM
Singhal Priya	Head of Development	Feb 22 '24	Sale	221.23	262	57,962	4,886	Feb 26 07:54 PM
Singhal Priya	Head of Development	Feb 16 '24	Option Exercise	0.00	1,208	0	5,429	Feb 21 09:27 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 16 '24	Option Exercise	0.00	5,037	0	52,506	Feb 21 09:39 PM
Gregory Ginger	EVP, Human Resources	Feb 16 '24	Option Exercise	0.00	4,704	0	14,341	Feb 21 09:36 PM
Izzar Rachid	Head of Global Product Strat.	Feb 16 '24	Option Exercise	0.00	2,017	0	10,014	Feb 21 09:33 PM
Kramer Robin	Chief Accounting Officer	Feb 16 '24	Option Exercise	0.00	1,345	0	6,354	Feb 21 09:31 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 16 '24	Option Exercise	0.00	6,720	0	20,692	Feb 21 09:29 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 16 '24	Option Exercise	0.00	1,260	0	9,624	Feb 21 09:28 PM
Singhal Priya	Head of Development	Feb 16 '24	Sale	221.49	108	23,921	5,148	Feb 21 09:27 PM
Rowinsky Eric K	Director	Feb 15 '24	Buy	222.54	455	101,256	20,629	Feb 20 09:13 PM
Singhal Priya	Head of Development	Feb 12 '24	Sale	239.45	419	100,330	4,516	Feb 13 06:06 PM
Izzar Rachid	Head of Global Product Strat.	Feb 09 '24	Option Exercise	0.00	1,515	0	9,081	Feb 13 06:00 PM
Singhal Priya	Head of Development	Feb 09 '24	Option Exercise	0.00	1,212	0	5,309	Feb 13 06:06 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 09 '24	Option Exercise	0.00	2,272	0	9,529	Feb 13 06:04 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 09 '24	Option Exercise	0.00	3,257	0	17,555	Feb 13 06:03 PM
Kramer Robin	Chief Accounting Officer	Feb 09 '24	Option Exercise	0.00	833	0	5,523	Feb 13 06:01 PM
Gregory Ginger	EVP, Human Resources	Feb 09 '24	Option Exercise	0.00	2,158	0	11,778	Feb 13 06:14 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 09 '24	Option Exercise	0.00	2,575	0	50,021	Feb 13 05:56 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 08 '24	Option Exercise	0.00	2,335	0	15,063	Feb 09 08:03 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 08 '24	Option Exercise	0.00	2,101	0	7,895	Feb 09 08:01 PM
Kramer Robin	Chief Accounting Officer	Feb 08 '24	Option Exercise	0.00	788	0	4,943	Feb 09 08:06 PM
Gregory Ginger	EVP, Human Resources	Feb 08 '24	Option Exercise	0.00	1,635	0	10,118	Feb 09 08:14 PM
Izzar Rachid	Head of Global Product Strat.	Feb 08 '24	Option Exercise	0.00	2,043	0	8,187	Feb 09 08:11 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 08 '24	Option Exercise	0.00	2,190	0	48,101	Feb 09 08:16 PM
Singhal Priya	Head of Development	Feb 02 '24	Sale	245.93	634	155,920	4,097	Feb 05 06:38 PM
Singhal Priya	Head of Development	Feb 01 '24	Option Exercise	0.00	1,828	0	5,292	Feb 05 06:38 PM
Singhal Priya	Head of Development	Dec 11 '23	Sale	248.00	110	27,280	3,464	Dec 12 05:06 PM
Kramer Robin	Chief Accounting Officer	Dec 08 '23	Option Exercise	0.00	351	0	4,325	Dec 12 05:02 PM
Singhal Priya	Head of Development	Dec 08 '23	Option Exercise	0.00	426	0	3,780	Dec 12 05:06 PM
BIOGEN INC.	10% Owner	Sep 26 '23	Sale	0.50	6,000,000	3,000,000	17,652,466	Sep 28 05:30 PM
Singhal Priya	Head of Development	Sep 05 '23	Sale	269.43	431	116,124	3,354	Sep 06 06:06 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Sep 01 '23	Option Exercise	0.00	5,285	0	14,060	Sep 06 06:08 PM
Singhal Priya	Head of Development	Sep 01 '23	Option Exercise	0.00	1,668	0	4,592	Sep 06 06:06 PM

Open in Screener

VSTM

Verastem Inc

Jul 26 • 04:00PM ET

2.96

Dollar change -0.01
Percentage change -0.34	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VTWO IWC VTWG RSSL DFAC FESM

Index	RUT	P/E	-	EPS (ttm)	-4.40	Insider Own	19.89%	Shs Outstand	25.28M	Perf Week	-10.84%
Market Cap	74.98M	Forward P/E	-	EPS next Y	-3.05	Insider Trans	-0.25%	Shs Float	20.29M	Perf Month	-3.58%
Income	-105.52M	PEG	-	EPS next Q	-0.98	Inst Own	48.54%	Short Float	11.17%	Perf Quarter	-67.88%
Sales	0.00M	P/S	-	EPS this Y	2.05%	Inst Trans	-	Short Ratio	2.38	Perf Half Y	-75.11%
Book/sh	0.99	P/B	2.99	EPS next Y	21.27%	ROA	-86.34%	Short Interest	2.27M	Perf Year	-69.04%
Cash/sh	4.39	P/C	0.67	EPS next 5Y	1.74%	ROE	-210.18%	52W Range	2.54 - 14.22	Perf YTD	-63.64%
Dividend Est.	-	P/FCF	-	EPS past 5Y	24.76%	ROI	-108.99%	52W High	-79.18%	Beta	0.19
Dividend TTM	-	Quick Ratio	4.40	Sales past 5Y	-45.06%	Gross Margin	-	52W Low	16.54%	ATR (14)	0.33
Dividend Ex-Date	-	Current Ratio	4.40	EPS Y/Y TTM	0.92%	Oper. Margin	0.00%	RSI (14)	38.65	Volatility	8.78% 8.49%
Employees	73	Debt/Eq	1.14	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	18.21
Option/Short	Yes / Yes	LT Debt/Eq	1.09	EPS Q/Q	-34.31%	Payout	-	Rel Volume	0.89	Prev Close	2.97
Sales Surprise	-	EPS Surprise	-22.16%	Sales Q/Q	-	Earnings	May 09 AMC	Avg Volume	953.92K	Price	2.96
SMA20	-4.88%	SMA50	-37.86%	SMA200	-65.05%	Trades		Volume	851,429	Change	-0.34%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-21-23	Resumed	BTIG Research	Buy	$27
Sep-27-23	Initiated	B. Riley Securities	Buy	$21
Jun-15-23	Upgrade	Mizuho	Neutral → Buy	$24 → $36
Sep-07-22	Resumed	Alliance Global Partners	Buy	$6
Apr-29-22	Resumed	Cantor Fitzgerald	Overweight	$6 → $5
Apr-14-22	Initiated	RBC Capital Mkts	Outperform	$5
Mar-09-22	Initiated	Truist	Buy	$6
Jul-01-21	Initiated	Alliance Global Partners	Buy	$6
May-24-21	Upgrade	BTIG Research	Neutral → Buy	$8
Jun-20-19	Downgrade	BTIG Research	Buy → Neutral
May-10-19	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-13-18	Initiated	BTIG Research	Buy	$17
May-02-18	Initiated	Seaport Global Securities	Buy	$14
Mar-08-18	Initiated	B. Riley FBR, Inc.	Buy	$15
Sep-07-17	Reiterated	H.C. Wainwright	Buy	$6.50 → $10
Apr-13-17	Initiated	Oppenheimer	Outperform
Mar-24-17	Reiterated	H.C. Wainwright	Buy	$5 → $6.50
Sep-29-15	Downgrade	Raymond James	Strong Buy → Outperform
Sep-29-15	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-29-15	Downgrade	Jefferies	Buy → Hold

Show Previous Ratings

Jul-23-24 11:20PM	Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants (Business Wire) -17.55%
04:05PM	Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants (Business Wire)
Jul-15-24 11:42AM	Verastem (VSTM) Begins Dosing in Solid Tumors Study in China (Zacks)
04:52AM	Verastem announces dosing of first patient in trial of KRAS G12D inhibitor (Clinical Trials Arena)
Jul-12-24 07:30AM	Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics (Business Wire) +12.75%
07:30AM	Loading…
Jul-08-24 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-01-24 07:30AM	Verastem Oncology Announces Addition to Russell 3000 and Russell Microcap Indexes (Business Wire) +9.06%
Jun-19-24 07:00AM	GenFleet Receives IND Approval from China's NMPA for GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a Phase I/II Clinical Trial Treating Advanced Solid Tumor Patients with KRAS G12D Mutation (PR Newswire)
Jun-12-24 10:22AM	Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments (PR Newswire)
Jun-06-24 06:45AM	7 F-Rated Stocks to Avoid at All Costs in June (InvestorPlace)
Jun-03-24 09:17AM	Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
May-24-24 12:28PM	Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data (Zacks) -66.17%
11:43AM	Is the Stock Market Open on Memorial Day 2024? (InvestorPlace)
11:23AM	7 Things to Know About the Upcoming Nvidia (NVDA) Stock Split (InvestorPlace)
11:01AM	NLST Stock Alert: Micron Faces $445 Million Verdict in Netlist Patent Trial (InvestorPlace)
10:45AM	Loading…
10:45AM	What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday? (Benzinga)
10:39AM	Why Is Verastem (VSTM) Stock Down 62% Today? (InvestorPlace)
08:47AM	ASCO 2024: Verastems combo therapy for pancreatic cancer hits early trial success (Pharmaceutical Technology)
07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
07:00AM	Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer (Business Wire)
May-23-24 05:01PM	Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer? (Business Wire)
May-09-24 10:58PM	VSTM Stock Earnings: Verastem Beats EPS for Q1 2024 (InvestorPlace)
04:56PM	Verastem: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
May-07-24 07:30AM	Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference (Business Wire)
Apr-18-24 04:05PM	Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer (Business Wire) -5.63%
Apr-09-24 07:00AM	GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting (PR Newswire)
Apr-04-24 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.43%
Mar-18-24 07:00AM	Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer (Business Wire)
Mar-14-24 09:54PM	VSTM Stock Earnings: Verastem Misses EPS for Q4 2023 (InvestorPlace)
04:53PM	Loading…
04:53PM	Verastem: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates (Business Wire)
Mar-11-24 07:30AM	Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Womens Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs (Business Wire)
Mar-05-24 05:27PM	Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
04:30PM	Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024 (Business Wire)
Feb-15-24 03:12AM	Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc (GuruFocus.com)
Feb-07-24 05:02PM	Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM) (GuruFocus.com)
07:15AM	3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024 (InvestorPlace)
Jan-29-24 07:00AM	Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers (Business Wire) +7.12%
Jan-22-24 08:15AM	Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy (Zacks)
Jan-18-24 04:00PM	Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) (Business Wire) -6.48% +7.51%
Jan-11-24 07:00AM	Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference (Business Wire)
Jan-05-24 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-18-23 07:00AM	Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics (Business Wire)
Dec-13-23 09:08AM	3 Off-the-Beaten-Path Stocks Poised for Substantial Growth (InvestorPlace) +10.67%
07:00AM	Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Dec-03-23 04:17PM	Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential (InvestorPlace)
Nov-22-23 12:00PM	All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy (Zacks)
Nov-13-23 07:00AM	New Healthcare Professional Component of Lets Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach (Business Wire)
Nov-08-23 05:52PM	Verastem: Q3 Earnings Snapshot (Associated Press Finance) -5.66%
04:12PM	Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Nov-07-23 07:00AM	First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer (Business Wire) +6.65%
Nov-06-23 07:00AM	Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population (Business Wire)
Oct-26-23 04:05PM	Verastem Oncology Strengthens Executive Leadership Team with Key Appointments (Business Wire) -7.85%
Oct-18-23 04:50PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-14-23 12:30PM	Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer (Business Wire)
Oct-06-23 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-28-23 02:15PM	Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit (Business Wire) -5.13%
Sep-05-23 07:00AM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire)
Sep-04-23 01:23PM	3 Penny Stocks That Can Triple Your Money in the Next 12 Months (InvestorPlace)
Aug-28-23 07:00AM	Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers (Business Wire)
Aug-08-23 05:46PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Jul-11-23 07:00AM	Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer (Business Wire)
Jul-10-23 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +9.50%
Jul-05-23 04:05PM	Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Jun-16-23 05:00AM	Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Jun-15-23 04:06PM	Verastem Stock Is Outperforming 92% Of The Market And It Just Surged (Investor's Business Daily) +16.09%
04:00PM	Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
May-31-23 09:11AM	Verastem Oncology Announces Reverse Stock Split (Business Wire)
May-25-23 05:05PM	Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib (Business Wire) +125.55%
May-16-23 07:00AM	Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors (Business Wire)
May-09-23 04:56PM	Verastem: Q1 Earnings Snapshot (AP Finance)
04:05PM	Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
May-02-23 07:45AM	Strong week for Verastem (NASDAQ:VSTM) shareholders doesn't alleviate pain of five-year loss (Simply Wall St.)
May-01-23 07:00AM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire) +12.65%
Apr-26-23 04:05PM	New Data from Interim Analysis of Verastem Oncologys RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting (Business Wire) +5.14%
Apr-18-23 07:05AM	Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days (Business Wire)
Apr-06-23 05:39PM	7 Very Undervalued Penny Stocks to Buy in April 2023 (InvestorPlace) -6.12%
04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-15-23 07:00AM	New Verastem Oncology Initiative, Lets Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer (Business Wire)
Mar-14-23 04:05PM	Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress (Business Wire)
Feb-02-23 07:00AM	Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers (Business Wire) +8.65%
Jan-30-23 12:00PM	Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) -5.80%
Jan-24-23 05:46PM	Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock (Business Wire)
05:45PM	Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Jan-18-23 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-11-23 06:24AM	individual investors who own 37% along with institutions invested in Verastem, Inc. (NASDAQ:VSTM) saw increase in their holdings value last week (Simply Wall St.) +11.00%
Dec-15-22 04:30PM	Verastem Oncology Appoints Rob Gagnon to Board of Directors (Business Wire) -5.00% -7.63%
Nov-08-22 08:22AM	Verastem Third Quarter 2022 Earnings: US$0.092 loss per share (vs US$0.13 loss in 3Q 2021) (Simply Wall St.)
Nov-03-22 04:05PM	Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress (Business Wire)
Oct-20-22 07:00AM	Verastem Oncology Appoints Anil Kapur to Board of Directors (Business Wire)
Oct-07-22 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.49%
Oct-04-22 07:00AM	Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates (Business Wire) -34.60%
Sep-19-22 09:31AM	10 Long-Term Stocks to Buy During Recessions (Insider Monkey)
Aug-23-22 12:23PM	Investors five-year losses grow to 64% as the stock sheds US$34m this past week (Simply Wall St.)
Aug-08-22 07:00AM	Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress (Business Wire) +7.56%
Jul-27-22 11:40AM	Is Verastem (NASDAQ:VSTM) Using Too Much Debt? (Simply Wall St.)
Jul-07-22 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.93%
Jun-27-22 11:17AM	What You Need To Know About Verastem, Inc.'s (NASDAQ:VSTM) Investor Composition (Simply Wall St.)

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Calkins Daniel	Chief Financial Officer	Jul 09 '24	Sale	2.62	7	18	47,560	Jul 11 07:00 AM
Calkins Daniel	Chief Financial Officer	Jun 24 '24	Sale	3.15	28	88	47,290	Jun 26 04:30 PM
Stuglik Brian M	Director	Jun 20 '24	Sale	3.21	335	1,075	97,045	Jun 20 08:27 PM
Paterson Dan	President and CEO	Jun 20 '24	Sale	3.21	183	587	236,063	Jun 20 08:28 PM
Gagnon Robert E.	Director	Jun 20 '24	Sale	3.21	131	421	35,310	Jun 20 08:29 PM
Calkins Daniel	Chief Financial Officer	Jun 20 '24	Sale	3.16	67	212	47,318	Jun 20 08:30 PM
Stuglik Brian M	Director	Jun 17 '24	Sale	3.49	593	2,070	89,047	Jun 20 08:27 PM
Gagnon Robert E.	Director	Jun 17 '24	Sale	3.49	283	988	27,108	Jun 20 08:29 PM
Paterson Dan	President and CEO	Jun 17 '24	Sale	3.49	244	852	86,246	Jun 20 08:28 PM
Calkins Daniel	Chief Financial Officer	Apr 05 '24	Sale	10.87	6	65	8,535	Apr 08 04:30 PM
Calkins Daniel	Chief Financial Officer	Mar 25 '24	Sale	12.02	25	300	8,541	Mar 27 04:30 PM
Calkins Daniel	Chief Financial Officer	Mar 20 '24	Sale	11.07	55	609	8,566	Mar 21 04:31 PM
Stuglik Brian M	Director	Mar 19 '24	Sale	10.38	273	2,834	89,640	Mar 20 05:32 PM
Paterson Dan	President and CEO	Mar 19 '24	Sale	10.38	182	1,889	86,490	Mar 20 05:34 PM
Gagnon Robert E.	Director	Mar 19 '24	Sale	10.38	130	1,349	27,391	Mar 20 05:36 PM
Stuglik Brian M	Director	Mar 18 '24	Sale	10.71	537	5,751	89,913	Mar 20 05:32 PM
Gagnon Robert E.	Director	Mar 18 '24	Sale	10.71	283	3,031	27,521	Mar 20 05:36 PM
Paterson Dan	President and CEO	Mar 18 '24	Sale	10.71	244	2,613	86,672	Mar 20 05:34 PM
Gagnon Robert E.	Director	Feb 06 '24	Sale	13.70	9,204	126,095	27,804	Feb 07 04:00 PM
Gagnon Robert E.	Director	Jan 12 '24	Sale	10.95	9,204	100,784	37,008	Jan 17 04:00 PM
Calkins Daniel	Chief Financial Officer	Jan 05 '24	Sale	8.50	6	51	8,621	Jan 09 04:03 PM
Calkins Daniel	Chief Financial Officer	Dec 26 '23	Sale	8.08	25	202	8,350	Dec 28 04:04 PM
Calkins Daniel	Chief Financial Officer	Dec 20 '23	Sale	7.93	57	452	8,375	Dec 21 04:01 PM
Stuglik Brian M	Director	Dec 19 '23	Sale	7.73	274	2,118	90,450	Dec 20 04:00 PM
Paterson Dan	President and CEO	Dec 19 '23	Sale	7.73	183	1,415	86,916	Dec 20 04:01 PM
Gagnon Robert E.	Director	Dec 19 '23	Sale	7.73	130	1,005	46,212	Dec 20 04:03 PM
Stuglik Brian M	Director	Dec 18 '23	Sale	7.64	487	3,721	90,724	Dec 20 04:00 PM
Gagnon Robert E.	Director	Dec 18 '23	Sale	7.64	284	2,170	46,342	Dec 20 04:03 PM
Paterson Dan	President and CEO	Dec 18 '23	Sale	7.64	244	1,864	87,099	Dec 20 04:01 PM
Calkins Daniel	Vice President of Finance	Oct 05 '23	Sale	7.30	5	36	8,432	Oct 10 04:31 PM
Calkins Daniel	Vice President of Finance	Sep 25 '23	Sale	9.40	25	235	8,437	Sep 25 04:46 PM
Calkins Daniel	Vice President of Finance	Sep 21 '23	Sale	9.31	232	2,160	8,462	Sep 25 04:46 PM
Stuglik Brian M	Director	Sep 19 '23	Sale	9.84	274	2,696	91,211	Sep 20 04:15 PM
Paterson Dan	President and CEO	Sep 19 '23	Sale	9.84	183	1,801	87,343	Sep 20 04:15 PM
Gagnon Robert E.	Director	Sep 19 '23	Sale	9.84	130	1,279	46,626	Sep 20 04:15 PM
Stuglik Brian M	Director	Sep 18 '23	Sale	9.91	478	4,737	91,485	Sep 20 04:15 PM
Gagnon Robert E.	Director	Sep 18 '23	Sale	9.91	278	2,755	46,756	Sep 20 04:15 PM
Paterson Dan	President and CEO	Sep 18 '23	Sale	9.91	240	2,378	87,526	Sep 20 04:15 PM

Open in Screener

FBIO

Fortress Biotech Inc

Jul 26 • 04:00PM ET

2.25

Dollar change -0.35
Percentage change -13.46	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

FBIO Fortress Biotech Inc daily Stock Chart

Held by: VTI VXF IWC FESM

Index	-	P/E	-	EPS (ttm)	-19.52	Insider Own	25.59%	Shs Outstand	20.41M	Perf Week	4.65%
Market Cap	45.92M	Forward P/E	-	EPS next Y	-3.21	Insider Trans	0.68%	Shs Float	15.19M	Perf Month	32.35%
Income	-62.85M	PEG	-	EPS next Q	-1.22	Inst Own	15.68%	Short Float	9.72%	Perf Quarter	30.81%
Sales	85.11M	P/S	0.54	EPS this Y	44.39%	Inst Trans	-11.51%	Short Ratio	7.13	Perf Half Y	7.66%
Book/sh	1.19	P/B	1.89	EPS next Y	31.92%	ROA	-25.46%	Short Interest	1.48M	Perf Year	-73.14%
Cash/sh	4.21	P/C	0.53	EPS next 5Y	25.50%	ROE	-179.27%	52W Range	1.24 - 9.00	Perf YTD	-25.25%
Dividend Est.	-	P/FCF	-	EPS past 5Y	22.28%	ROI	-61.58%	52W High	-75.00%	Beta	1.65
Dividend TTM	-	Quick Ratio	1.21	Sales past 5Y	26.66%	Gross Margin	66.76%	52W Low	81.45%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	1.33	EPS Y/Y TTM	-37.33%	Oper. Margin	-137.40%	RSI (14)	57.02	Volatility	14.33% 8.48%
Employees	186	Debt/Eq	3.85	Sales Y/Y TTM	32.48%	Profit Margin	-73.85%	Recom	1.00	Target Price	10.75
Option/Short	Yes / Yes	LT Debt/Eq	3.43	EPS Q/Q	67.40%	Payout	-	Rel Volume	2.47	Prev Close	2.60
Sales Surprise	-7.79%	EPS Surprise	40.46%	Sales Q/Q	4.84%	Earnings	May 15 AMC	Avg Volume	207.07K	Price	2.25
SMA20	13.15%	SMA50	18.53%	SMA200	8.52%	Trades		Volume	511,583	Change	-13.46%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-15-24	Resumed	ROTH MKM	Buy	$10
Aug-04-22	Initiated	Ladenburg Thalmann	Buy	$6
Oct-02-20	Initiated	The Benchmark Company	Buy	$9
Dec-18-19	Initiated	B. Riley FBR	Buy	$9
Feb-28-18	Initiated	B. Riley FBR, Inc.	Buy	$10
Jul-11-17	Initiated	Rodman & Renshaw	Buy	$11
Mar-22-17	Initiated	JMP Securities	Mkt Outperform
Oct-03-16	Initiated	ROTH Capital	Buy	$9

Jul-25-24 08:30AM	Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027 (GlobeNewswire) +5.69%
07:30AM	Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma (GlobeNewswire)
Jul-15-24 08:50AM	Here Is Why Bargain Hunters Would Love Fast-paced Mover Fortress Biotech (FBIO) (Zacks)
08:00AM	GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research (GlobeNewswire)
Jul-11-24 04:05PM	Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors (GlobeNewswire) +12.57%
04:05PM	Loading…
Jul-05-24 04:05PM	Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (GlobeNewswire)
Jul-02-24 08:00AM	Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
07:00AM	Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab (GlobeNewswire)
Jun-24-24 07:30AM	Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission (GlobeNewswire)
Jun-21-24 04:01PM	Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jun-20-24 08:30AM	Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
08:00AM	Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jun-17-24 08:30AM	Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy (GlobeNewswire)
May-16-24 08:30AM	Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) (GlobeNewswire)
08:00AM	Fortress Biotech to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase (GlobeNewswire)
10:53PM	Loading…
May-15-24 10:53PM	FBIO Stock Earnings: Fortress Biotech Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:32PM	Fortress Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Journey Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase (GlobeNewswire)
08:30AM	Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-14-24 11:14AM	Fortress Biotech Says First Patient Dosed in Phase 2 Study of Triplex (MT Newswires)
08:30AM	Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation (GlobeNewswire)
May-13-24 04:01PM	Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:30AM	Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
May-10-24 08:30AM	Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
May-07-24 08:30AM	Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024 (GlobeNewswire)
May-02-24 04:01PM	Mustang Bio Announces Closing of $4 Million Public Offering (GlobeNewswire)
May-01-24 04:01PM	Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer (GlobeNewswire)
Apr-29-24 08:00PM	Mustang Bio Announces Pricing of $4 Million Public Offering (GlobeNewswire)
08:00AM	Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds (GlobeNewswire)
08:30AM	Loading…
Apr-25-24 08:30AM	Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024 (GlobeNewswire)
Apr-24-24 07:30AM	Avenue Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Apr-11-24 12:24PM	3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024 (InvestorPlace)
Mar-28-24 10:53PM	FBIO Stock Earnings: Fortress Biotech Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -7.83%
04:05PM	Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
09:00AM	Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases (GlobeNewswire)
Mar-25-24 08:30AM	Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024 (GlobeNewswire)
Mar-22-24 08:30AM	Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-21-24 04:01PM	Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-18-24 04:05PM	Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:30AM	Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea (GlobeNewswire)
08:00AM	Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors (GlobeNewswire)
Mar-15-24 08:30AM	Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 (GlobeNewswire) +15.18%
08:15AM	Avenue Therapeutics Receives Positive Listing Determination from Nasdaq (GlobeNewswire)
Mar-13-24 08:30AM	Journey Medical Corporation to Participate in the 36th Annual ROTH Conference (GlobeNewswire) -5.45%
Mar-12-24 08:30AM	Fortress Biotech to Participate in 36th Annual ROTH Conference (GlobeNewswire)
Mar-11-24 04:05PM	Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:30AM	Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting (GlobeNewswire)
08:00AM	Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting (GlobeNewswire)
Mar-07-24 07:30AM	Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13R 2-targeted CAR T-Cells in High-Grade Glioma (GlobeNewswire) -6.55%
Mar-04-24 08:30AM	Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease (GlobeNewswire) -5.76%
Feb-22-24 08:30AM	Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy (GlobeNewswire)
Feb-02-24 02:40PM	Lindsay Rosenwalds Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries (News Direct) -6.09%
Jan-29-24 08:00AM	Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market (GlobeNewswire)
Jan-11-24 08:30AM	Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire)
08:15AM	Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire)
08:00AM	Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference (GlobeNewswire)
Jan-09-24 05:02PM	Insider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires 50,000 ... (GuruFocus.com) -6.19% -8.49%
Jan-05-24 09:15AM	Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds (GlobeNewswire)
08:30AM	Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea (GlobeNewswire)
Jan-04-24 08:30AM	Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol (GlobeNewswire)
Jan-03-24 04:01PM	Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -7.81%
Jan-02-24 04:05PM	Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million (GlobeNewswire) -10.63%
08:30AM	Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) (GlobeNewswire)
Dec-29-23 08:20AM	Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -22.62%
Dec-11-23 08:30AM	Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-06-23 08:30AM	Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics (PR Newswire)
08:30AM	Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd. (GlobeNewswire)
08:00AM	Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea (GlobeNewswire)
Dec-05-23 08:30AM	Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance (GlobeNewswire)
Dec-01-23 08:30AM	Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting (GlobeNewswire) +9.60%
Nov-16-23 11:18PM	Insider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires Shares ... (GuruFocus.com) +46.15%
Nov-14-23 04:29PM	Fortress Biotech: Q3 Earnings Snapshot (Associated Press Finance)
04:10PM	Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Fortress Biotech Announces Closing of $10.0 Million Public Offering (GlobeNewswire)
Nov-13-23 05:00PM	Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-10-23 08:15AM	Fortress Biotech Announces Pricing of $10.0 Million Public Offering (GlobeNewswire) -37.02%
Nov-09-23 05:05PM	Fortress Biotech Announces Launch of Proposed Public Offering (GlobeNewswire)
Nov-07-23 04:01PM	Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -10.50%
Nov-02-23 03:00PM	Avenue Therapeutics Announces Closing of $5.0 Million Public Offering (GlobeNewswire) +15.48%
09:28AM	Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-23 09:15AM	Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering (GlobeNewswire) +5.29%
08:30AM	Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire)
Oct-30-23 02:15PM	Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-26-23 12:30PM	Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
09:00AM	Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13R 2 targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma (GlobeNewswire)
Oct-20-23 08:30AM	Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn (Minocycline Hydrochloride Extended-Release Tablets, 105 mg) (GlobeNewswire) -8.37%
Oct-18-23 08:30AM	Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer (GlobeNewswire) -12.69%
Oct-16-23 09:00AM	Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1 (GlobeNewswire)
Oct-09-23 12:50PM	Fortress Biotech Announces Reverse Stock Split (GlobeNewswire) -12.48%
Oct-05-23 08:30AM	Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference (GlobeNewswire)
Oct-02-23 12:53PM	Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds (GlobeNewswire) +7.85%
Sep-21-23 08:30AM	Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference (GlobeNewswire) -5.93%
Sep-07-23 08:30AM	Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
08:15AM	Mustang Bio to Participate in Upcoming September 2023 Investor Conferences (GlobeNewswire)
Sep-06-23 08:30AM	Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +9.61%
08:00AM	Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations (GlobeNewswire)
Sep-05-23 08:30AM	Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -10.79%

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Jul 11 '24	Buy	7.48	5,000	37,418	127,500	Jul 15 04:05 PM
Jin David	Chief Financial Officer	Jul 10 '24	Buy	7.50	500	3,750	500	Jul 12 08:42 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Jul 09 '24	Buy	7.39	5,000	36,971	122,500	Jul 11 08:00 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Jul 08 '24	Buy	7.35	5,000	36,764	117,500	Jul 10 08:30 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Jun 28 '24	Buy	1.64	20,000	32,724	2,893,905	Jul 01 08:40 AM
Klein Dov	Director	May 20 '24	Sale	1.89	10,000	18,900	53,400	May 20 04:56 PM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	May 16 '24	Buy	1.76	10,000	17,589	2,873,905	May 20 05:00 PM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Jan 05 '24	Buy	2.38	50,000	118,770	2,863,905	Jan 09 08:15 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Nov 14 '23	Buy	1.70	1,567,515	2,664,776	2,597,440	Nov 16 05:50 PM
WEISS MICHAEL S	See Remarks	Nov 14 '23	Buy	1.70	147,058	249,999	1,130,520	Nov 16 05:46 PM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Sep 26 '23	Buy	0.28	100,000	28,330	15,449,091	Sep 27 08:20 AM
Fortress Biotech, Inc.	10% Owner	Sep 08 '23	Buy	0.72	418,410	301,255	1,032,390	Sep 12 09:02 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Aug 18 '23	Buy	9.34	10,000	93,400	112,500	Aug 21 08:30 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Aug 17 '23	Buy	11.75	10,000	117,500	102,500	Aug 21 08:30 AM

BIIB

Biogen Inc

VSTM

Verastem Inc

FBIO

Fortress Biotech Inc

Upgrade your FINVIZ experience